How peptides are made, and why purity varies

What a peptide actually is

A peptide is a short chain of amino acids, the same building blocks that make up protein. The difference between a peptide and a protein is mostly length: chains of roughly fifty units or fewer are called peptides, and longer chains fold into proteins. That length is what makes them practical to build.

Amino acids are small molecules that link end to end like beads on a string. A short string is a peptide, a long one folds into a protein, and the boundary between the two is a convention rather than a hard rule. Most of the compounds discussed in peptide circles sit well under fifty units, and many are under ten.

That shortness matters for a practical reason. A protein is far too large and too dependent on its folded shape to assemble reliably in a machine, but a short chain can be built unit by unit in a defined order. Chemists have been doing exactly that since the 1960s, when Bruce Merrifield described a method for growing a peptide chain while it stayed attached to a solid support [1]. That paper is the ancestor of essentially every synthetic peptide sold today.

It helps to hold on to one idea before going further. A peptide is defined by its exact sequence, the specific amino acids in a specific order. Change one unit and you have a different molecule, which may do something else entirely or nothing at all. Everything that follows about purity is really a question about how many of the molecules in a given batch have the sequence they are supposed to have.

How a peptide gets built in a lab

Almost every synthetic peptide is made by solid-phase synthesis, a method that anchors the first amino acid to a solid bead and adds the rest one at a time. Each cycle couples a new unit, washes away the excess, and repeats. Modern machines run those cycles automatically, hundreds of times over.

The method is called solid-phase peptide synthesis, usually shortened to SPPS. The first amino acid is chemically attached to a tiny insoluble bead, and the chain is grown while it stays tethered there. Because the growing chain is stuck to something solid, everything else can simply be rinsed away between steps, which is the trick that makes the whole process workable [1].

Each round has the same shape. A protective cap is removed from the end of the chain, the next amino acid is coupled on, and the excess reagents are washed out. Then it happens again. A twenty-unit peptide means roughly twenty of these cycles, each involving several chemical operations, and contemporary instruments automate the entire sequence so that a chain can be assembled without a person handling each step [2].

When the chain is complete it is cleaved off the bead, the remaining protective groups are stripped, and the crude mixture is purified, most often by chromatography, a separation technique that pushes a sample through a column so its components come out at different times. The material that emerges at the expected time is collected, dried, and becomes the powder in a vial.

Why no synthesis run comes out perfectly clean

Every coupling step is a chemical reaction, and no reaction runs to one hundred percent. A small fraction of chains miss a unit or stop growing early, so the final batch contains the target peptide plus a family of near-identical relatives that differ by one or two amino acids.

This is the part that is easy to miss. Suppose each coupling step works 99 percent of the time, which is a good result. Over a thirty-unit chain, those small failures compound, and the fraction of chains that made it through every single step without a stumble is meaningfully less than 99 percent. The rest are still there, still peptides, just not quite the intended one.

The by-products have names that describe how they went wrong. A deletion sequence is a chain that skipped a unit. A truncated sequence stopped growing partway and never finished. Others carry a leftover protective group, or have had a sensitive amino acid subtly altered by the harsh chemistry used along the way.

What makes these difficult is precisely that they are close cousins of the target. Analytical chemists working on synthetic human C-peptide had to use high-resolution mass spectrometry, an instrument that measures molecular weight very precisely, combined with liquid chromatography just to identify and accurately quantify the structurally related impurities in their preparations [3]. If separating them takes that level of instrumentation in a research setting, they are not something a supplier can wave away.

What a purity percentage really describes

A purity figure is the share of material that showed up as the target peak on a chromatogram, the graph produced when a sample is separated by chromatography. It describes what the instrument detected under one set of conditions. It is a useful number, but it is a measurement result, not a guarantee of identity.

When a certificate says 99 percent, it almost always means that the target peak accounted for 99 percent of the total signal area on a chromatogram run under a particular method. That is a real measurement and worth having. It is also narrower than most people read it as.

Two limitations matter. The first is that a purity number says nothing on its own about identity: it tells you one component dominated the sample, not that the component is the peptide named on the label. Confirming identity requires a separate measurement, typically mass spectrometry, checking that the molecular weight matches what the sequence predicts. The second is that a method only detects what it is designed to detect, so an impurity that co-elutes with the target, meaning it comes off the column at the same time, can hide inside the main peak.

Regulatory analysis of generic peptide products treats these as distinct questions, assessing identity, content, and the impurity profile through a combination of orthogonal methods rather than any single figure [5]. A single percentage on its own, with no method named and no supporting data, is a claim rather than a characterization.

Why the leftover fraction matters

The remaining percent is not inert filler. It is made of molecules that resemble the target closely enough to have been built alongside it, and regulators assess some of them for immunogenicity, the chance that the immune system reacts to a substance. Similarity to the real thing is exactly what makes them worth checking.

The intuitive reading of "1 percent impurity" is that a tiny bit of something irrelevant came along. The reality is less comfortable. Those molecules are structurally related to the peptide itself, because they were assembled in the same reaction from the same parts.

That similarity is why the topic gets formal attention. Peptide-related impurities are evaluated for immunogenicity, the potential to provoke an immune response, and the assessment frameworks developed for synthetic peptide drugs exist specifically because impurities that differ only slightly from the parent molecule can still be recognized by the immune system [6]. Work on generic teriparatide products applied exactly this kind of analysis to impurities identified in real marketed products [7].

Two points are worth keeping straight. This research concerns regulated pharmaceutical products made under manufacturing standards, where impurity profiles are documented and controlled. Materials sold outside that system carry the same chemistry without the same scrutiny. And none of it says a given impurity will cause a problem in a given person. It says the question is real enough that regulators require an answer, which is a meaningfully different claim from a supplier asserting a number.

How quality actually gets verified

Real verification compares a batch against a reference standard, a well-characterized sample that defines what the correct molecule looks like. Laboratories combine separation and mass measurement to confirm identity and quantify what else is present. A certificate without named methods and a traceable standard describes very little.

The anchor of the whole system is the reference standard. It is a thoroughly characterized batch that serves as the definition of the correct material, and every other batch is measured against it. Without one, a laboratory can report that two samples differ but cannot say which is right, and establishing these standards is treated as foundational infrastructure for synthetic peptide quality rather than a formality [4].

On top of that sits a set of complementary measurements: chromatography to separate components and quantify their proportions, mass spectrometry to confirm the molecular weight matches the intended sequence, and further methods to check water content, residual solvents, and counter-ions. Regulatory guidance for generic peptides expects this combination rather than any single test, because each method is blind to something the others catch [5].

For a reader, the practical version is a short list of questions. Does the certificate name the methods used, or only report numbers? Is it tied to a specific batch, or generic to the product? Was the testing done by the seller or an independent laboratory? A document that reports a percentage with no method, no batch, and no traceable standard is marketing material in the shape of a lab report.